Rita Patrocínio de Jesus

Rita Patrocínio de Jesus

Auto-generated profile, based on publicly available information

Rita Patrocínio de Jesus

Serviço de Infeciologia, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RPRita Patrocinio-Jesus
Rita Patrocinio-Jesus
FPFrancesca Peruzzu
Francesca Peruzzu
A 31-year-old man with well-controlled infection with the human immunodeficiency virus presented to the clinic with a 1-week history of a painless genital rash and a 2-day history of fever and sore throat. Three weeks earlier, he had had condomless intercourse with a new male partner. On physical examination, a macular rash and painful lymphadenopathy were observed in the right inguinal area (Panel A), and two ulcerated lesions and several umbilicated pustules were observed on the penis (Panel B). Tests for syphilis, chlamydia, and gonorrhea were negative. Antimicrobial therapy for possible lymphogranuloma venereum and chancroid was initiated. Five days after the initial presentation, the patient returned with vesiculopustular lesions on the face and hands. Polymerase-chain-reaction assays of swabs obtained from lesions on the genitals and the hands were positive for monkeypox. In classic cases of monkeypox, patients have a febrile prodrome followed by a rash that may appear on any part of the body, with lesions that evolve simultaneously. In the current global outbreak of monkeypox, painless anogenital lesions — often without a prodrome — are being observed in persons who have had close contact with an infected person or persons, including men who have sex with men. Within 2 weeks after his initial presentation, the patient’s lesions had abated without specific intervention. Additional examples of monkeypox genital lesions that were observed in other patients are shown in Panels C and D.

11 September 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
VBVítor Borges
Vítor Borges
MDMariana Perez Duque
Mariana Perez Duque
JMJoão Vieira Martins
João Vieira Martins
PVPaula Vasconcelos
Paula Vasconcelos
RFRita Ferreira
Rita Ferreira
João Paulo GomesJoão Paulo Gomes
João Paulo Gomes
Pathogen genome sequencing during epidemics enhances our ability to identify and understand suspected clusters and investigate their relationships. Here, we combine genomic and epidemiological data of the 2022 mpox outbreak to better understand early viral spread, diversification and transmission dynamics. By sequencing 52% of the confirmed cases in Portugal, we identified the mpox virus sublineages with the highest impact on case numbers and fitted them into a global context, finding evidence that several international sublineages probably emerged or spread early in Portugal. We estimated a 62% infection reporting rate and that 1.3% of the population of men who have sex with men in Portugal were infected. We infer the critical role played by sexual networks and superspreader gatherings, such as sauna attendance, in the dissemination of mpox virus. Overall, our findings highlight genomic epidemiology as a tool for the real-time monitoring and control of mpox epidemics, and can guide future vaccine policy in a highly susceptible population.

2 March 2023 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
RJRita Patrocínio de Jesus
Rita Patrocínio de Jesus
HHHamish Houston
Hamish Houston
ASAnnemiek H J Schutte
Annemiek H J Schutte
SMStephen Morris-Jones
Stephen Morris-Jones
NSNeil Stone
Neil Stone
GPGabriele Pollara
Gabriele Pollara
To assess the performance of T2Candida for the diagnosis of invasive candidiasis (IC) against gold standards of candidaemia or consensus IC definitions, and to evaluate the impact of T2Candida on antifungal drug prescribing. A retrospective review was undertaken of all T2Candida (T2MR technology, T2 Biosystems) performed from October 2020 to February 2022. T2Candida performance was evaluated against confirmed candidaemia or against proven/probable IC within 48 hours of T2Candida, and its impact on antifungal drug prescriptions. T2Candida was performed in 61 patients, with 6 (9.8%) positive results. Diagnostic performance of T2Candida against candidaemia had a specificity of 85.7% and negative predictive value (NPV) of 96.8%. When comparing T2Candida results with consensus definitions of IC, the specificity and NPV of T2Candida was respectively 90% (54/60) and 98.2% (54/55) for proven IC, and 91.4% (53/58) and 96.4% (53/55) for proven/probable IC. Antifungals were initiated in three of six patients (50%) with a positive T2Candida result. Thirty-three patients were receiving empirical antifungals at the time of T2Candida testing, and a negative result prompted cessation of antifungals in 11 (33%) patients, compared with 6 (25%) antifungal prescriptions stopped following negative beta-d-glucan (BDG) testing in a control population (n = 24). T2Candida shows high specificity and NPV compared with evidence of Candida bloodstream infection or consensus definitions for invasive Candida infection, and may play an adjunctive role as a stewardship tool to limit unnecessary antifungal prescriptions.

2 October 2020 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
RJRita Patrocínio de Jesus
Rita Patrocínio de Jesus
RSRaquel Silva
Raquel Silva
EAElzara Aliyeva
Elzara Aliyeva
LLLuís Lopes
Luís Lopes
MPMihran Portugalyan
Mihran Portugalyan
PFPaulo Freitas
Paulo Freitas
As SARS-CoV-2 and its related clinical syndrome (COVID-19) became a pandemic worldwide, questions regarding its clinical presentation, infectivity, and immune response have been the subject of investigation. We present a case of a patient previously considered recovered from nosocomially transmitted asymptomatic COVID-19 illness, who presented with new respiratory, radiological, and RT-PCR findings consistent with COVID-19, while on high-dose prednisolone due to a suspected secondary demyelinating disease. Importantly, it led to three subsequent cases within patient’s household after discharge from the hospital. After reviewing this case in light of current evidence and debates surrounding SARS-CoV-2 RT-PCR results, we hypothesize that patients on corticosteroids may have particular viral shedding dynamics and should prompt a more conservative approach in regard to isolation discontinuation and monitoring.

3 August 2022 in Cureus
Verified
Journal Article
Open access
CLCatarina Lameiras
Catarina Lameiras
RJRita Patrocínio de Jesus
Rita Patrocínio de Jesus
BFBárbara Flor-De-Lima
Bárbara Flor-De-Lima
JSJoana Silva
Joana Silva
PPPatrícia Pacheco
Patrícia Pacheco
Varicella-zoster virus (VZV) myelitis is a rare complication of herpes zoster. Diagnosing and treating this entity may be challenging. Clinical outcomes vary and neurological sequelae may be seen despite treatment. We report a case of a 43-year-old woman with human immunodeficiency virus type 1 (HIV-1) infection (CD4 cell count 191 cells/µL - 14%; undetectable viral load) who was started on antiretroviral treatment eight months before. She presented with VZV meningitis and transverse myelitis and concomitant thoracic vesicular rash at the dermatomal level T6. Neurological examination revealed neck stiffness, paraplegia, sensory level below T4, and autonomic dysfunction. Magnetic resonance imaging (MRI) revealed signs of myelitis from C4 to T10 and VZV DNA by polymerase chain reaction (PCR) was positive (20,00,000 cp/mL) in the cerebrospinal fluid (CSF). The patient completed four weeks of intravenous acyclovir and systemic corticosteroids. Repeat lumbar puncture returned negative for VZV PCR and MRI showed spinal cord improvement. However, only partial neurological improvement was observed after six months. Some features of the present case may be associated with an unfavorable outcome, including high VZV viral load in the CSF and rapid progression of neurological deficits to paraplegia and sphincter dysfunction. Moreover, the recovery of CD4+ cells from 4% to 14% after starting antiretroviral treatment might also have contributed to the extension of myelopathy. Further studies are needed to improve the understanding of VZV myelitis course and optimize its treatment.

27 February 2026 in Revista Portuguesa de Doenças Infecciosas (RPDI)
Verified
Journal Article
Open access
PDF file
MAMaria Alves
Maria Alves
RJRita Jesus
Rita Jesus
Discussão do caso: Apresenta-se o caso de uma mulher de 56 anos, em situação de sem-abrigo, com antecedentes de infeção crónica pelo vírus da hepatite B e consumo excessivo de álcool e tabaco, que recorreu ao serviço de urgência por dermatose dolorosa e pruriginosa com quatro meses de evolução. O exame objetivo revelou múltiplas lesões ovóides, planas, de base larga e aspeto mucoso, algumas umbilicadas, predominantemente localizadas na região genital e em áreas intertriginosas. A doente referia contacto sexual sem preservativo em contexto de agressão sexual, três semanas antes do surgimento das lesões. Laboratorialmente, apresentava VDRL 1/128 e TPHA positivo, tendo sido excluídas outras etiologias infeciosas. A biópsia cutânea confirmou o diagnóstico de condylomata lata, manifestação característica da sífilis secundária. Apesar do abandono precoce do seguimento, verificou-se posteriormente resolução clínica e serológica. Conclusão: Este caso ilustra uma apresentação exuberante e atípica da sífilis secundária, salientando a sua natureza proteiforme e o impacto dos determinantes sociais da saúde na gravidade da doença e no atraso diagnóstico, particularmente em populações socialmente vulneráveis.